Building a Business Case for Biopharmaceutical QbD Implementation (Peer Reviewed) - The author describes a methodology for developing a per product qualitative and semi-qualitative business case for a

ADVERTISEMENT

Building a Business Case for Biopharmaceutical QbD Implementation (Peer Reviewed)
The author describes a methodology for developing a per product qualitative and semi-qualitative business case for applying QbD to a biopharmaceutical product.


BioPharm International
Volume 25, Issue 8, pp. 40-47

REFERENCES

1. T. Fuhr, M. Holcomb, and P. Rutten, "Why Quality-by-Design Should be on the Executive Team's Agenda: Developing New Strategies for New Times," in Outpacing Change in Pharma Operations, M. Losch, and U. Schrader, Eds. (McKinsey & Co., December, 2009) pp. 195–203.

2. B. Schmidt, "Implementing Quality by Design: Are you ready, or not?" Aug. 4, 2010, http://www.pharmaqbd.com/schmidt_ready_for_qbd/, accessed Jul. 17, 2012.

3. H. Winkle, "Regulatory Modernization- FDA's Desired State for Product Quality," presentation at the BioProcess International Conference (Providence, RI, Sept. 21, 2010).

4. H.N. Winkle and M.M. Nasr, Pharm. Tech. Eur. 23 (9), 10–19 (2011).

5. H.L. Levine, S.D. Jones, and A.D. Kanarek, Bioprocess Int. 9 (1), 64 (2011).

6. FDA, "Advancing Regulatory Science at FDA. A Strategic Plan," Aug. 2011, p. 14. http://www.fda.gov/regulatoryscience, accessed Jul. 17, 2012.

7. T. Agres, Drug Disc. Devel. 14 (3), 10–11 (2011).

8. ICH Q8R2, Pharmaceutical Development, (August 2009).

9. J. Woodcock, "Pharmaceutical GMP's for the 21st Century: FDA's New Initiative on Drug Product Quality," Oct. 29, 2002, http://www.fda.gov/ohrms/dockets/ac/02/slides/3902s1-11-Woodcock.ppt, accessed Jul. 17, 2012.

10. M. Welin, EU Regulatory Feedback, presentation at ISPE meeting (Brussels, Sept. 2010).

11. J.A.C. Lim et al., Bioprocess Int. 8 (10), 62–70 (2010).

12. B. Junker, BioPharm Int. 22 (5), 40–50 (2009).

13. C. Woelbeling, Pharmaceutical Engineering 28 (3), 36–48 (2008).

14. B. Chatterjee, Pharmaceutical Processing 26 (4), 8–9 (2011).

15. E. David, T. Tramontin, and R. Zemmel, Nat. Rev. Drug Disc. 8, 609–610 (2009).

16. E. David, T. Tramontin, and R. Zemmel, R., The Road to Positive R&D Returns, http://www.mckinseyquarterly.com/Health_Care/Pharmaceuticals/The_road_to_positive_.../. 2010, accessed Jul. 17, 2012.

17. Z. Shahrokh, S. Price, and M. Voloch, BioPharm Int. 24 (8), 35–43 (2011).

18. S.D. Jones, and H.L. Levine, "Integrating Quality by Design into Early Process Development," presentation at IBC Preclinical Scale Bioprocessing Conference (Boston, MA, Nov. 1–3, 2010).

19. Center for Chemical Process Safety, The Business Case for Process Safety, (American Institute of Chemical Engineers, 2nd Ed, 2010).

20. S. Martin-Moe et al., J. Pharm. Sci. 100 (8), 3031–3043 (2011).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here